FDA Will Revise Investigator Disqualification Regs In Response To GAO Report
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will revise its regulations to prevent clinical investigators who are disqualified from running trials for one product type to continue leading studies for other FDA-regulated categories.
You may also be interested in...
FDA’s Wayback Machine: Clinical Investigator Disqualifications Could Trigger Wide-Ranging Audits
Any clinical trial that an FDA-disqualified investigator was involved in may be subject to scrutiny, the agency says in explaining a final rule.
Informed Consent Guidance Allows Discussion Of Specimen "Donation"
Sponsors of clinical trials can now include language in informed consent forms explaining that subjects are "donating" their blood, tissue or urine samples; previously, the term had been discouraged because of concern that it released sponsors from liability.
Informed Consent Guidance Allows Discussion Of Specimen "Donation"
Sponsors of clinical trials can now include language in informed consent forms explaining that subjects are "donating" their blood, tissue or urine samples; previously, the term had been discouraged because of concern that it released sponsors from liability.